Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

No difference in bleeding risk between subcutaneous enoxaparin and heparin for thromboprophylaxis in end-stage renal disease.

Chan KE, Thadhani RI, Maddux FW.

Kidney Int. 2013 Sep;84(3):555-61. doi: 10.1038/ki.2013.152. Epub 2013 May 15.

PMID:
23677243
2.

Initiative to improve thromboprophylactic enoxaparin exposure in hospitalized patients with renal impairment.

Elsaid KA, Collins CM.

Am J Health Syst Pharm. 2012 Mar 1;69(5):390-6. doi: 10.2146/ajhp110319.

PMID:
22345418
3.

Use of enoxaparin in end-stage renal disease.

Lai S, Coppola B.

Kidney Int. 2013 Sep;84(3):433-6. doi: 10.1038/ki.2013.163.

PMID:
23989356
4.

Efficacy and safety of high-dose thromboprophylaxis in morbidly obese inpatients.

Wang TF, Milligan PE, Wong CA, Deal EN, Thoelke MS, Gage BF.

Thromb Haemost. 2014 Jan;111(1):88-93. doi: 10.1160/TH13-01-0042. Epub 2013 Oct 17.

5.

Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial.

Stellbrink C, Nixdorff U, Hofmann T, Lehmacher W, Daniel WG, Hanrath P, Geller C, Mügge A, Sehnert W, Schmidt-Lucke C, Schmidt-Lucke JA; ACE (Anticoagulation in Cardioversion using Enoxaparin) Study Group.

Circulation. 2004 Mar 2;109(8):997-1003. Epub 2004 Feb 16.

6.

[The risk of bleeding associated with low molecular weight heparin in patients with renal failure].

Lai S, Barbano B, Cianci R, Gigante A, Di Donato D, Asllanaj B, Dimko M, Mariotti A, Morabito S, Pugliese F.

G Ital Nefrol. 2010 Nov-Dec;27(6):649-54. Italian.

PMID:
21132647
7.

Low-molecular-weight heparin and mortality in acutely ill medical patients.

Kakkar AK, Cimminiello C, Goldhaber SZ, Parakh R, Wang C, Bergmann JF; LIFENOX Investigators.

N Engl J Med. 2011 Dec 29;365(26):2463-72. doi: 10.1056/NEJMoa1111288.

8.

Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials.

Raskob GE, Gallus AS, Pineo GF, Chen D, Ramirez LM, Wright RT, Lassen MR.

J Bone Joint Surg Br. 2012 Feb;94(2):257-64. doi: 10.1302/0301-620X.94B2.27850.

PMID:
22323697
9.

Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.

Goldhaber SZ, Leizorovicz A, Kakkar AK, Haas SK, Merli G, Knabb RM, Weitz JI; ADOPT Trial Investigators.

N Engl J Med. 2011 Dec 8;365(23):2167-77. doi: 10.1056/NEJMoa1110899. Epub 2011 Nov 13.

10.

Bleeding during enoxaparin treatment more common with age over 75 years and severe renal insufficiency.

Despotovic N, Erceg P, Nikolic-Despotovic M, Milosevic DP, Davidovic M.

Drugs Aging. 2007;24(9):777-9.

PMID:
17727306
11.

Comparison of cost, effectiveness, and safety of injectable anticoagulants used for thromboprophylaxis after orthopedic surgery.

Shorr AF, Sarnes MW, Peeples PJ, Stanford RH, Happe LE, Farrelly E.

Am J Health Syst Pharm. 2007 Nov 15;64(22):2349-55.

PMID:
17989444
12.

Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease.

Merli G, Spiro TE, Olsson CG, Abildgaard U, Davidson BL, Eldor A, Elias D, Grigg A, Musset D, Rodgers GM, Trowbridge AA, Yusen RD, Zawilska K; Enoxaparin Clinical Trial Group.

Ann Intern Med. 2001 Feb 6;134(3):191-202.

PMID:
11177331
13.

Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial.

Hull RD, Schellong SM, Tapson VF, Monreal M, Samama MM, Nicol P, Vicaut E, Turpie AG, Yusen RD; EXCLAIM (Extended Prophylaxis for Venous ThromboEmbolism in Acutely Ill Medical Patients With Prolonged Immobilization) study.

Ann Intern Med. 2010 Jul 6;153(1):8-18. doi: 10.7326/0003-4819-153-1-201007060-00004.

PMID:
20621900
14.

A feasible strategy for preventing blood clots in critically ill patients with acute kidney injury (FBI): study protocol for a randomized controlled trial.

Robinson S, Zincuk A, Larsen UL, Ekstrøm C, Toft P.

Trials. 2014 Jun 13;15:226. doi: 10.1186/1745-6215-15-226.

15.

Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention.

Montalescot G, White HD, Gallo R, Cohen M, Steg PG, Aylward PE, Bode C, Chiariello M, King SB 3rd, Harrington RA, Desmet WJ, Macaya C, Steinhubl SR; STEEPLE Investigators.

N Engl J Med. 2006 Sep 7;355(10):1006-17.

16.

[The impact of thromboprophylaxis with enoxaparin on bleeding rate in rejuvenating facelift procedures].

Kuz'min VV, Buzov DA, Nudel'man SV, Golubkov NA.

Khirurgiia (Mosk). 2014;(7):66-71. Russian.

PMID:
25146545
17.

Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials.

Davidson BL, Büller HR, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob GE, Segers AE, Lensing AW; Matisse Investigators.

J Thromb Haemost. 2007 Jun;5(6):1191-4.

18.

Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease.

Kleber FX, Witt C, Vogel G, Koppenhagen K, Schomaker U, Flosbach CW; THE-PRINCE Study Group.

Am Heart J. 2003 Apr;145(4):614-21.

PMID:
12679756
19.

Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial.

Eriksson BI, Dahl OE, Huo MH, Kurth AA, Hantel S, Hermansson K, Schnee JM, Friedman RJ; RE-NOVATE II Study Group.

Thromb Haemost. 2011 Apr;105(4):721-9. doi: 10.1160/TH10-10-0679. Epub 2011 Jan 12.

PMID:
21225098
20.

Subcutaneous enoxaparin for therapeutic anticoagulation in hemodialysis patients.

Pon TK, Dager WE, Roberts AJ, White RH.

Thromb Res. 2014 Jun;133(6):1023-8. doi: 10.1016/j.thromres.2014.03.036. Epub 2014 Mar 24.

PMID:
24718051

Supplemental Content

Support Center